423 related articles for article (PubMed ID: 21358417)
1. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration
J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
3. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
6. Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
Eworuke E; Shinde M; Hou L; Paterson MJ; Jensen PB; Maro JC; Rai A; Scarnecchia D; Pennap D; Woronow D; Ghosh RE; Welburn S; Pottegard A; Platt RW; Lee H; Bradley MC
BMJ Open; 2023 Apr; 13(4):e070985. PubMed ID: 37068898
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
[TBL] [Abstract][Full Text] [Related]
8. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Nixon RM; Müller E; Lowy A; Falvey H
Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L
Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379
[TBL] [Abstract][Full Text] [Related]
10. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Desai RJ; Ashton CM; Deswal A; Morgan RO; Mehta HB; Chen H; Aparasu RR; Johnson ML
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):233-40. PubMed ID: 21786364
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
13. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
Ong HT
J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
Chang CH; Lin JW; Wu LC; Lai MS
J Clin Oncol; 2011 Aug; 29(22):3001-7. PubMed ID: 21690476
[TBL] [Abstract][Full Text] [Related]
15. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R
Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension.
Xi GL; Cheng JW; Lu GC
Am J Hypertens; 2008 May; 21(5):546-52. PubMed ID: 18437146
[TBL] [Abstract][Full Text] [Related]
18. [Tendency and prospect of the development of new ARBs].
Kim S
Nihon Rinsho; 2002 Oct; 60(10):1881-6. PubMed ID: 12397678
[TBL] [Abstract][Full Text] [Related]
19. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
Ishii M
Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Antoniou T; Camacho X; Yao Z; Gomes T; Juurlink DN; Mamdani MM
CMAJ; 2013 Sep; 185(12):1035-41. PubMed ID: 23836857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
